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Is hyperhomocysteinaemia a risk factor for recurrent venous 
thrombosis?
Martin den Heijer, Henk J  Biom, Wim B J  Gerrits, Frits R Rosendaai, Hans L Haak, Pierre W Wijermans, 
Gerard M J  Bos
Summary
Several studies have shown a relation between
»
hyperhomocysteinaemia and arterial vascular disease. We 
looked at the association between hyperhomocysteinaemia 
and venous thrombosis which could be clinically important 
as hyperhomocysteinaemia is easily corrected by vitamin 
supplementation.
We studied 185 patients with a history of recurrent 
venous thrombosis and 220 controls from the general 
population. Homocysteine concentrations were measured 
before and 6 h after oral methionine loading. We 
defined hyperhomocysteinaemia as the homocysteine 
concentration above the fasting or the postmethionine 
value found for the 90th percentile of the controls. Of the 
185 patients with recurrent thrombosis, 46 (25%) had 
fasting homocysteine concentrations above the 90th 
percentile or the controls (odds ratio is 3-1 [1-8-5-5]). 
After adjustment for age, sex, and menopausal status the 
odds ratio was 2-0 (l-5-2*7). Similar results were found for 
the post-methionine value (unadjusted odds ratio 3-1 
[1-7-5-5], adjusted 2*6 [1-9-3-5]).
Hyperhomocysteinaemia is a common risk factor for 
recurrent venous thrombosis and can lead to a two-fold or 
three-fold increase in risk.
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Introduction
Hyperhomocysteinaemia is a disorder of methionine 
metabolism. Several studies have shown a relation 
between m ild hyperhomocysteinaemia and vascular 
disease.1,2 Howevers little attention has been directed 
towards venous thrombosis3 which is surprising because 
of the high frequency of venous thrombosis among 
patients with classical homocysteinuria.3 We present the 
results of a study on the relation between m ild 
hyperhomocysteinaemia and venous thrombosis in 
patients with recurrent venous thrombosis.
Patients and methods
Patients were selected from the files of the anticoagulant clinic of 
The Hague. In the Netherlands^ virtually all patients with a 
history of recurrent venous tiirombosis have long-term coumarin 
therapy and are registered at an anticoagulant clinic. All patients 
between 20 and 90 years who had had two or more episodes of 
venous thrombosis were invited to take part. Pregnancy was the 
only exclusion criterion. Of the 473 patients approached3 185 
participated (39%).
We recruited the control group through a general practice in 
The Hague. We invited 2812 people aged 20-90 from this 
practice to take part in a health survey of risk factors for 
cardiovascular disease. 532 people agreed to participate and the 
first 220 formed the control group.
We obtained a short medical history of all patients by interview 
and all controls by questionnaire. A methionine-loading test was 
done on all subjects. This test consisted of a basal homocysteine 
measurement (after overnight fasting) and a second 
homocysteine measurement 6 h after oral methionine loading 
(OT g L-methionine per kg bodyweight in 200 mL orange juice).4 
A diet poor in protein was given to the patients during the tests.
We obtained blood samples from the antecubital vein in 5 mL 
Vacutainer tubes and 4*5 mL EDTA vacuum glass tubes for 
determination of the homocysteine and vitamin concentrations 
and routine laboratory measurements (creatinine3 aspartate 
aminotransferase j alanine aminotransferase) gammaglutamyl
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Figure: Homocysteine concentrations in patients and controls
Fasting (A) and post-methlonlne (B) homocysteine concentration fn 
thrombosis patients and controls. Dotted lines Indicate 90th percentiles 
of distribution of control subjects.
transpeptidase, alkaline phosphatase, and a whole blood count). 
The IiDTA-samples for homocysteine measurement were 
immediately placed on ice and centrifuged at 3500 g for 5 min 
within 2 h. The plasma was separated and stored at ~20°C until 
analysis.
Routine laboratory tests were done with a Kodak Ektachem 
Processor. Vitamin B I2 and folic acid concentrations were 
measured in serum samples stored at —70°C with the Dualcount 
SPNB (solid phase no boil) Radioassay (Diagnostic Product 
Corporation, Los Angeles, USA). The total homocysteine 
concentration in plasma was measured in the laboratory of 
Paediatrics and Neurology of the Nijmegen University 
Hospital (HJB) by an automated high-performance liquid 
chromatography method with reverse phase separation and 
fluorescent detection (Gilson 232-401 sample processor, 
Spectra Physics 8800 solvent delivery system and Spectra Physics 
LC 304 fluorometer)» essentially according to the method by 
Fisker strand et a I.1
The methionine-loading test was used to detect 
hyperhomocysteinaemia. We analysed both fasting and post­
loading homocysteine concentrations because there is no 
consensus whedter hyperhomocysteinaemia should be defined as 
an abnormal homocysteine concentration, either in the fasting 
state or after methionine loading. As a cut-off point we used the 
90th percentile of the distribution of the control subjects. We also 
analysed the data with the SOth, 95th, and 97*5th perccntile as 
cut-olT points.
Cases
n=105
Controls
n~220
Odds ratio
Fasting homocysteine concentrations
>90th percentile (18-6 jimol/L) 
*s90th percentile (18-6 (imol/L)
46
139
21
199
3*1 (1-8-5* 5)
Post-methionine homocysteine concentrations
>90th percentile {58-8 jjunol/L)
^90th percentile (58-8 ^mol/L)
44
141
20
200
3-1 ( JL-7—5*5)
Table 1: Homocysteine concentrations and risk of recurrent 
venous thrombosis
We calculated crude odds ratios as estimates of the relative risk 
and used Miettinen’s test-based 95% C l ,6 Adjusted odds ratios 
were calculated with a logistic regression model. These odds 
ratios reflected the risk of recurrent thrombosis for people with 
hyperhomocysteinaemia compared with normal individuals when 
the data were adjusted for age, sex, and menopausal status.7 To 
find a dose-response relation we stratified the homocysteine 
concentrations of both cases and controls into quartiles and 
calculated the odds ratios for the three higher levels and 
compared them with the lowest reference level.” We also 
calculated an aetiologic fraction, which represented the 
proportion of all cases of recurrent thrombosis attributable to 
hyperhomocysteinaemia., provided that the relation between 
hyperhomocysteinaemia and darombosis is a causal one.''
The study protocol was approved by the ethics committee of 
the Leyenburg Hospital.
Results
The mean age of the patient group invited was 67 (range 
20-97) years old. For patients who took part mean age 
was 61 (range 23-88) years compared with 51 (21-84) 
years in controls. The ratio between pulmonary embolism 
and deep venous thrombosis as main diagnosis was 1/1*6 
in die group of patients invited and 1/1*5 in patients 
taking part in die study. The median time between 
the first episode of thrombosis and the study was 17 
(range 1-58) years; the median time between the last 
episode of thrombosis and the study was 7 (range 1-30) 
years.
The figure shows the individual homocysteine fasting 
and post-methionine values. The cut-off point was 
defined as the 90th percentile of die distribution among 
the control subjects (18-6 (xmol/L for the fasting value 
and 58-8 fxmol/L for the post-methionine value). These 
cut-off points are comparable to the reference values 
(mean +2 SD) obtained from healthy^ younger volunteers 
in the laboratory of Nijmegen with values of 183 15, and 
19 jxmol/L for die fasting homocysteine concentration 
and 54, 51, and 69 jxmol/L for die post-metiiionine 
homocysteine concentration for men, premenopausal 
women, and postmenopausal women, respectively.
Among the patients with thrombosis, 46 (25%) had 
fasting homocysteine concentrations above die cut-off
Odds ratio
Fasting homocysteine concentrations
80th percentile (16-2 ^mol/L) 2*7 (l*8-4*3)
90th percentile (18*6 |xmol/L) 3-H 1-8-5-5)
95th percentile (22*2 |imol/L) 3*1 { l-4 -6 ’8)
97-5th percentile (27*7 |imol/L) 2’7(0'8~9'0)
Post-methlone homocysteine concentrations
80th percentile (51-7 nmol/L) 2* 5 (1*6~3*9) '
90th percentile (58*8 jimol/L) 3-1 ( l ‘7-5-5)
95th percentile (79-0 ^mol/L) 1*7 <Q*6-4‘3)
97*5th percentile {86*9 p.moi/L) 3*2 (0-6-8-4)
Table 2: Thrombosis risk for different cut-off points of 
homocysteine concentrations
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point of 18*6 jxmol/L, versus 21 in the control group 
(table 1). This yields a crude odds ratio of 3*1 (1*8-5*5). 
When the post-methionine homocysteine concentrations 
were used, 44 out of 185 patients (24%) had levels 
exceeding the cut-off point of 58-8 /xmol/L, versus 20 in 
the control group3 which gave a very similar odds ratio 
(unadjusted odds ratio 3-1 [1 *7—5*5]). Of the 46 patients 
who exceeded the fasting cut-off point 27 also exceeded 
the post-methionine 90th percentile value. The odds 
ratios for several other cut-off points are shown in 
table 2.
Our patients were selected from an anticoagulant clinic 
where they were registered because of recurrent venous 
thrombosis. In principle, for the diagnosis we relied on 
information of the referring physicians. We could also 
verify at least one diagnosis of venous thrombosis in 100 
of the 185 patients by means of a positive objective test 
(ventilation/perfusion scan, ultrasonography, or 
plethysmography) from the hospitals where patients were 
treated. In this subgroup we found 24 patients with a 
fasting homocysteine concentration above 18*6 jxmol/L 
(odds ratio 3-0 [1*6-5-8]) and 21 patients with a post­
methionine homocysteine concentration above 58-8 
jxmol/L (odds ratio 2*7 [1*3-5'3]).
Among the 220 controls, 7 (3-1%) had a history of 
venous thrombosis. 3 had fasting homocysteine above 
18-6 jjumol/L, and 2 had post-methionine homocysteine 
above 58*8 |xmol/L, giving an odds ratio of 8-1 (1*5-45*1) 
and 4-3 (0-4-52-3).
When we adjusted the results for age, sex, and 
menopausal status the odds ratios were slightly lower (2*0 
[I *5-2*7] for the fasting and 2*6 [1*9-3*5] for the post­
methionine value).
We stratified the homocysteine measurements of both 
patients and controls into quartiles and calculated the 
odds ratios for the three highest levels and compared 
them with the lowest (table 3). For fasting and post­
methionine values the odds ratio increased with 
homocysteine concentration.
The importance of hyperhomocysteinaemia as a risk 
factor for venous thrombosis is a function of the odds 
ratio and the prevalence in the general population. This is 
reflected by the aetiologic fraction. For the fasting value 
we calculated an aetiologic fraction of 0*17 (Cl 95% 
0*09-0*24). This implies that 17% of recurrent 
thrombosis may be due to hyperhomocysteinaemia 
(defined as a homocysteine concentration above 18*6 
|xmol/L). For the post-methionine value we calculated an 
aetiologic fraction of 0*16 (0*08-0*23, cut-off point: 58*8 
(junol/L).
Cases Controls Total Odds ratio
(n=185) (n=220) (n=405) (95% Cl)
Fasting homocysteine
concentrations
1st quartlle <11-0 fimol/L 36 68 104 1*
2nd quartlle 11-0-14*0 ^mol/L 35 66 101 1-0 (0-9-14)
3rd quartlle 14-0-17*0 jxmol/L 51 49 100 2*0 (14-3-6)
4th quartlle >17-0 fimol/L 63 37 100 3*2 (1-8-5-8)
Post-loading homocysteine
concentrations
1st quartlle <35*5 fimol/L 24 77 101 1*
2nd quartlle 35-5-43-0 pmol/L 47 55 102 2-7 (1-5-5-0)
3rd quartlle 43-0-54-0 jjutioI/L 50 52 102 3-1 (1*7—5*7)
4th quartile >54-0 jxmol/L 64 36 100 5-7 (34-10-5)
♦Reference category, odds ratlo=l. Test for trend, p<0-001.
Table 3: Thrombosis risk for strata of homocysteine 
concentrations
Vitamin B12 and folic acid were lower in the control 
subjects than in the patients, despite more vitamin 
supplements (median serum folic acid 6*0 [range 
2*3->24] ng/mL in patients and 5*8 [1*9-21*5] ng/mL in 
controls; median vitamin B12 408 [139-2387] pg/mLin 
patients and 288 [119->2400] pg/mL in controls).
Discussion
Our study shows that hyperhomocysteinaemia is a risk 
factor for recurrent venous thrombosis. Because the 
enrolment of incident cases with recurrent venous 
thrombosis would have taken a long time, we invited 
patients from an anti-coagulant clinic who were registered 
with a history of recurrent venous thrombosis.
This implicates a consession to diagnostic accuracy. So 
it is possible that some patients might not have had 
recurrent venous thrombosis according to present criteria 
of objective testing. However, if this is the case our results 
will only be diluted, and the real association between 
hyperhomocysteinaemia will be stronger. Furthermore, in 
100 patients we were able to trace medical records and 
found a positive objective test for venous thrombosis. In 
this subgroup we came to the same conclusion.
Up to now there is no consensus about reference values 
for plasma homocysteine concentrations. Most clinical 
studies on hyperhomocysteinaemia refer to laboratory 
reference values, usually obtained from healthy young 
volunteers. However, we found it more suitable to use a 
control group from the general population ie, the 
population where the patients came from.10 First we 
analysed our data at different cut-off points. A cut-off 
point at the 90th percentile of the control group is quite 
similar to the reference value based on a laboratory staff 
control group, which is younger and might have less co­
morbidity. This means that, with respect to these 
laboratory reference values hyperhomocysteinaemia is 
quite common in our control group, which is recruited 
from a general population.
We also found an increasing odds ratio with an 
increasing homocysteine concentration. This finding 
implies that there is no certain sharp cut-off point at all. 
We feel the issue of reference values concerning 
hyperhomocysteinaemia resembles the discussion on 
cholesterol, in so far that it is not very informative if a 
cholesterol value exceeds the reference value, but if it 
exceeds a certain concentration above which an increased 
risk of any clinical event exists. For homocysteine this 
would be already at the level of 14 jjumol/L for the fasting 
value and at the level of 35*5 (xmol/L for the post­
methionine homocysteine values (table 3).
Although only a modest odds ratio of 3 was 
determined, this observation is important because of the 
high prevalence of hyperhomocysteinaemia in the general 
population. This is reflected by the aetiologic fraction. We 
found an aetiologic fraction of 0*17 for the fasting value 
and 0*16 for the post-methionine value at the 90th 
percentile, meaning that hyperhomocysteinaemia can 
account for a substantial proportion of recurrent 
thrombosis.
Three previous case-control studies focused on the 
relation between hyperhomocysteinaemia and primary 
venous thrombosis. Bienvenu et al11 found increased 
homocysteine concentration in patients with venous 
thrombosis. However, this patient group was not 
homogeneous, since it included patients with Budd- 
Chiari syndrome and central retinal vein occlusion.
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Battstrom et al12 reported no significant difference 
between patients with venous thrombosis and controls 
which might have been because of the small sample size 
(42 cases and 42 controls). From their data we were able 
to calculate an odds ratio for primary thrombosis of 3-1 
(0*40-27’7). Falcon et aln found a high percentage of 
hyperhomocysteinaemia (18*8%) in patients with one or 
more events of venous thrombosis before 40 years. Our 
study shows that for recurrent thrombosis this observation 
can be extrapolated to all ages. Since we focused on 
recurrent thrombosis, the relative risk for a first 
thrombotic event cannot be inferred from our data.
The underlying mechanism by which 
hyperhomocysteinaemia can provoke thrombosis is 
unknown. There is some evidence that homocysteine 
contributes to endotiielial damage in the arterial vessel 
wall2-' but it is not clear whether this mechanism has a role 
in venous thrombosis. Another mechanism has been 
postulated by Rodgers et alMi|fi who found an in vitro 
effect of homocysteine on factor V activation and 
inhibition of thrombomodulin-dependent protein C 
activation. Moreover, an effect of homocysteine on 
thrombocyte aggregation has been reported.10
Hyperhomocysteinaemia may be the result of a 
hereditary defect in the enzymes involved in methionine 
metabolism or it might be acquired as a result of vitamin 
deficiency. It is not known whether the two types confer a 
similar risk of thrombosis. However ^ we did not find lower 
folic acid and vitamin B12 concentrations in patients than 
in controls. In fact we found higher homocysteine 
concentration at a given folic acid concentration in 
patients than in controls (data not shown.) This finding 
may suggest that some form of decreased enzyme activity 
and not vitamin deficiency leads to thrombosis,17
Several studies have shown that hyperhomo­
cysteinaemia can be corrected by vitamin 
supplementation.Whether vitamin supplementation 
for those with high levels of homocysteine will be 
beneficial with respect to prevention of (recurrent) venous 
thrombosis has to be further studied.17^
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